Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Quadrant Capital Group LLC

Quadrant Capital Group LLC raised its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 435.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 172,009 shares of the company’s stock after buying an additional 139,886 shares during the period. Quadrant Capital Group LLC’s holdings in Dr. Reddy’s Laboratories were worth $2,716,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in Dr. Reddy’s Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC grew its holdings in Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after acquiring an additional 1,820 shares during the period. Farther Finance Advisors LLC raised its position in Dr. Reddy’s Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after acquiring an additional 2,093 shares in the last quarter. Independence Bank of Kentucky lifted its holdings in Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock valued at $44,000 after acquiring an additional 2,220 shares during the last quarter. Finally, Allworth Financial LP boosted its position in shares of Dr. Reddy’s Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after purchasing an additional 2,230 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Stock Down 6.6 %

Shares of Dr. Reddy’s Laboratories stock opened at $12.37 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 1 year low of $12.36 and a 1 year high of $16.89. The stock has a 50-day moving average price of $13.33 and a 200 day moving average price of $14.50. The company has a market cap of $10.32 billion, a P/E ratio of 19.69 and a beta of 0.51.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.